KELYNIAM GLOBAL INC - KLYG STOCK NEWS

Kelyniam Global (OTC:KLYG), a producer of custom cranial implants, reported a strong Q2 2022 with a 20% revenue increase to $1,469,354, compared to $1,224,059 in Q2 2021. The CustomizedBone® implant significantly contributed to this growth. Operating income was $38,394, slightly down from $47,167 in the same period last year. Investments in infrastructure and marketing were funded without additional debt. The company anticipates continued sales momentum and benefits from returning surgical activity trends.

Kelyniam Global (OTC: KLYG) has appointed Desiree Webb as Vice President of Sales and Strategic Development. Webb, a current Board Member, brings over 20 years of healthcare experience, previously serving as Vice President of Orthopedics and Neuroscience at HCA Healthcare. Her focus will be on boosting the growth of craniofacial implants through collaboration with surgeons and distributors, alongside strengthening existing partnerships and expanding the product line. Kelyniam specializes in custom cranial and maxillo-facial implants, leveraging advanced medical-grade polymers.

Kelyniam Global (OTC:KLYG) announced its Q1 2022 results, revealing total revenue of $656,858, down 0.1% from $664,353 in Q1 2021. The gross margin slightly improved to $509,201 from $505,326, while operating income showed a loss of $5,924 compared to a profit of $13,806 a year earlier. CEO Ross Bjella noted that revenue figures were influenced by previous COVID-related demand, and he anticipates growth from the launch of CustomizedBone. The company is enhancing its sales team to target new contracts.

Kelyniam Global (OTC: KLYG) reported a record year in 2021, showcasing a 6.06% increase in total revenue to $2,664,434 and a remarkable 363.2% surge in operating income to $180,445. Net income rose by 43% to $201,741. The company announced a new strategic partnership with Fin-ceramica and received a patent for its Integrated Fixation System, enhancing its product offerings and intellectual property. Despite operational challenges from COVID-19, Kelyniam remains committed to growth and quality improvements, with the hiring of a new VP in Quality and Regulatory Affairs.

Kelyniam Global, Inc. (OTC: KLYG) announced a strategic licensing agreement with Fin-ceramica faenza spa to market a hydroxyapatite cranial implant. This product utilizes a bio-mimetic ceramic biomaterial, mainly consisting of hydroxyapatite, which enhances osteointegration and reduces post-operative infections compared to titanium implants. The CustomizedBone Service™ implant will be distributed by Kelyniam's salesforce of over 50 representatives starting in January. This partnership aligns with both companies' focus on innovative, patient-centered technology.

Kelyniam Global has received a US patent for its Integrated Fixation Tabs, enhancing its custom cranial implant offerings. The patent, filed in 2014 and valid until 2037, covers the inclusion of fixation appendages, potentially reducing surgical costs and time by eliminating the need for plates and screws. CEO Ross Bjella emphasizes that this innovation underscores Kelyniam's commitment to advancing medical technology. The company collaborates closely with surgeons to optimize implant placement, which can result in better cosmetic outcomes for patients.

Kelyniam Global (OTC:KLYG) reported third-quarter results for the period ended September 30, 2021. Despite a 0.9% revenue decline year-over-year to $1,953,267, the company experienced strong quarterly sales growth that offset earlier pandemic-related delays. Gross margin increased to $1,494,067, and net income rose to $222,353 compared to $117,651 last year. The company’s shares were upgraded to ‘Pink Current’ status on November 5, enhancing trading liquidity. Additionally, a $144,000 Paycheck Protection Plan loan was forgiven, benefiting the financials.

Kelyniam Global (OTC: KLYG) has submitted all documentation to establish itself as a 'Pink Current' filer ahead of the September 30, 2021 deadline. This move reflects the company's commitment to transparency for its shareholders. Until the review is complete, Kelyniam will remain a 'Pink Limited' filer but will continue to have its stock actively traded. The company also reported advancements regarding its Integrated Fixation System (IFS) patent and a positive acknowledgment from the FDA concerning its remediation plan on earlier observations.

Kelyniam Global (OTC:KLYG) reported financial results for the first half of 2021, showing a revenue decline of 3.25% to $1,224,059 compared to $1,265,235 in 2019. Operating income fell significantly from $181,395 to $47,167, with net income dropping from $184,567 to $5,544. Delays from the Covid-19 pandemic affected surgery schedules, impacting revenue generation. Kelyniam announced that $144,000 of its Paycheck Protection Plan loan will be forgiven, affecting the 3rd quarter's accounting. The company is also addressing FDA audit findings amid supply chain delays.